STOCK TITAN

Pediatrix Medical Group (MD) Stock News

MD NYSE

Pediatrix Medical Group, Inc. provides physician services for women, babies and children across hospital settings and office-based practices. Its recurring updates center on obstetrics, maternal-fetal medicine, neonatology, neonatal intensive care unit activity and other pediatric subspecialties, with revenue concentrated in neonatology and pediatric subspecialty care.

Company news also covers quarterly operating results, same-unit revenue trends, reimbursement and payor-mix factors, patient acuity, hospital contract administrative fees, practice acquisitions and dispositions, service expansions, clinical quality initiatives and neonatology education through NEO: The Conference for Neonatology.

Rhea-AI Summary

Pediatrix Medical Group (NYSE: MD) reported third-quarter 2026 earnings of $0.59 per diluted share, down from the prior-year quarter. Revenue rose 1.7% to $501.4 million, while net income fell to $47.0 million from $71.7 million. The prior-year quarter included a $20.9 million gain on investments in divested businesses. Adjusted EPS increased to $0.72 from $0.67.

Same-unit revenue grew 0.6%, with reimbursement-related factors and patient volume each contributing 0.3%. Adjusted EBITDA, an adjusted earnings measure excluding interest, taxes and certain other items, declined to $85.5 million from $87.3 million as expense growth exceeded revenue growth at existing units. Operating cash flow from continuing operations fell to $117.7 million from $138.1 million. Pediatrix spent $83.0 million on share repurchases and ended September with $311.9 million in cash and $578 million in debt. The company expects full-year adjusted EBITDA of $290 million to $300 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.93%
Tags
-
Rhea-AI Summary

Pediatrix Medical Group (MD) will host its third-quarter results conference call and webcast on October 29, 2026, at 9:00 a.m. ET. The discussion will cover the quarter ended September 30, 2026. A detailed results release will be issued that morning before securities markets open.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.86%
Tags
conferences
-
Rhea-AI Summary

Pediatrix Medical Group (NYSE: MD) reported second quarter 2026 net revenue of $487.8 million, up 4.0% from $468.8 million a year earlier, with net income of $39.8 million, or $0.49 diluted EPS. Adjusted EPS was $0.63 versus $0.53, and Adjusted EBITDA rose to $76.4 million from $73.2 million.

Same-unit revenue grew 1.9%, driven by a 4.0% increase from reimbursement factors, while same-unit patient volume declined 2.1%. Cash from continuing operations was $126.3 million, cash totaled $288.9 million, and total debt was $584 million. The company repurchased $42.7 million of shares and reaffirmed its 2026 Adjusted EBITDA outlook of $280–$300 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.87%
Tags
Rhea-AI Summary

Pediatrix Medical Group (NYSE: MD) provided an update on its second quarter 2026 business trends and outlook. The company reported that its Q2 payor mix remained stable and unchanged versus recent historical trends and internal expectations, and stated it has not experienced the unfavorable payor mix shifts reported by some other healthcare participants.

Pediatrix also reported no material changes in other net revenue-related trends compared to recent periods and reaffirmed its full-year 2026 Adjusted EBITDA outlook of $280 million to $300 million. The company scheduled its Q2 2026 earnings call for August 4, 2026 at 9:00 a.m. ET, with a detailed release to be issued that morning and a reconciliation of projected Adjusted EBITDA to GAAP measures available in its financial materials.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.34%
Tags
none
-
Rhea-AI Summary

Pediatrix Medical Group (NYSE:MD) announced publication of a large multicenter study on probiotic use and necrotizing enterocolitis (NEC) in extremely preterm infants, using its Clinical Data Warehouse.

The observational analysis of more than 10,000 infants found NEC rates rose in hospitals that sharply reduced probiotics after the FDA’s 2023 warning actions and withdrawals. The article suggests abrupt discontinuation may have unintended harmful consequences, but does not identify optimal probiotic strains, doses or products, and calls for prospective trials and clearer regulatory pathways.

The study, published in the Journal of Perinatology, is the first CDW project involving a nonprofit partner, the NEC Society, integrating patient-families into research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
none
-
Rhea-AI Summary

Pediatrix Medical Group (NYSE: MD) reported first-quarter 2026 results: net revenue $476.2M, net income $29.6M (EPS $0.36), Adjusted EPS $0.44, and Adjusted EBITDA $58.2M. Same-unit revenue rose 2.8% driven by reimbursement improvements; patient volume declined 1.6%.

Cash was $205.8M at March 31, 2026; total debt was $591M. The company reaffirmed 2026 Adjusted EBITDA guidance of $280M–$300M.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.05%
Tags
Rhea-AI Summary

Pediatrix Medical Group (NYSE: MD) will hold a first-quarter 2026 investor conference call and webcast on Tuesday, May 5, 2026 at 9:00 a.m. ET to discuss results for the quarter ended March 31, 2026. A detailed press release will be issued the morning of May 5, 2026 before markets open.

Investors can access the live webcast at www.pediatrix.com/investors.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.52%
Tags
conferences
-
Rhea-AI Summary

Pediatrix (NYSE: MD) expanded maternal-fetal medicine services in Middle Tennessee through a partnership with Tennessee Maternal-Fetal Medicine announced March 26, 2026.

The practice will operate as Maternal-Fetal Medicine Specialists of Tennessee across five Greater Nashville locations, adding four board-certified physicians and six advanced practice providers. The deal was a cash transaction and is expected to be immediately accretive to earnings; no further financial terms were disclosed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.29%
Tags
partnership
-
Rhea-AI Summary

Pediatrix (NYSE: MD) announced two senior clinical hires on March 24, 2026: James Barry, M.D., MBA, as Chief Clinical Quality & Transformation Officer and Jochen Profit, M.D., MPH, as Chief Quality Advisor. Both leaders will advance clinical quality, oversee CREQS activities, and support research, safety and systemwide improvement.

The appointments emphasize pediatrix's focus on evidence-based care, neonatology expertise, artificial intelligence in medicine, and national quality collaborations to improve outcomes and provider satisfaction.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.12%
Tags
none
Rhea-AI Summary

Pediatrix Medical Group (NYSE: MD) will host the 47th annual NEO: The Conference for Neonatology in Las Vegas, Feb. 25–27, 2026. The event gathers neonatal‑perinatal experts for sessions on clinical advances, neonatal POCUS training, ethics, respiratory care, nutrition, and accredited continuing education credits.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.89%
Tags
none

FAQ

What is the current stock price of Pediatrix Medical Group (MD)?

Pediatrix Medical Group (MD) last closed at $30.84.

What is the market cap of Pediatrix Medical Group (MD)?

The market cap of Pediatrix Medical Group (MD) is approximately $2.4B.